<?xml version="1.0" encoding="utf-8"?>


<DOCUMENT xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dart3.xsd">

<DOCUMENT-NAME ACODE="10800">증권발행실적보고서</DOCUMENT-NAME>
<FORMULA-VERSION ADATE="20220117">2.6</FORMULA-VERSION>
<COMPANY-NAME AREGCIK="00199252">에이치엘비</COMPANY-NAME>


<BODY>

<COVER>
<COVER-TITLE ATOC="Y" AASSOCNOTE="COVER">증권발행실적보고서</COVER-TITLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="152"></COL>
<COL WIDTH="430"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" COLSPAN="2" WIDTH="600" HEIGHT="53"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30">금융감독원장 귀하</TD>
<TD CLASS="NORMAL" ALIGN="RIGHT" WIDTH="439" HEIGHT="30">2022년      12월     09일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53">회       사       명 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53">에이치엘비 주식회사</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53">대   표     이   사 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53">진 양 곤, 김 동 건</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30">본  점  소  재  지 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">울산광역시 울주군 온산읍 당월로 216-53</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(전  화) 02-3453-4414</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(홈페이지) http://www.hlbkorea.com</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30">작  성  책  임  자 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(직  책) 경영전략팀장              (성  명) 한 영 인</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(전  화) 02-3453-4414</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53"></TD>
</TR>
</TBODY>
</TABLE>
<P></P>
</COVER>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">

<LIBRARY>
<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-1-0">Ⅰ. 발행개요</TITLE>
<P></P>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">1. 기업개요</TITLE>

<TABLE-GROUP ACLASS="CRP_OTLN" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">상장구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">기업규모</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">업종구분</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TU WIDTH="200" HEIGHT="30" AUNIT="CRP_RGS_CLS" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="2">코스닥</TU>
<TU WIDTH="200" HEIGHT="30" AUNIT="CRP_SCL" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="2">중소기업</TU>
<TU WIDTH="200" HEIGHT="30" AUNIT="CRP_CODE" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="31">기타 운송장비 제조업</TU>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">2. 발행 개요</TITLE>

<TABLE-GROUP ACLASS="PBL_OTLN" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">발행총액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TU WIDTH="200" HEIGHT="53" AUNIT="DST_SMR" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="3">기타</TU>
<TE WIDTH="200" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER" ACODE="INC_SL_PO_SUM">240,972,681,600</TE>
<TE WIDTH="200" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER" ACODE="NOTE">주주배정후 실권주 일반공모 유상증자</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-2-0">Ⅱ. 청약 및 배정에 관한 사항</TITLE>
<P></P>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">1. 청약 및 납입일정</TITLE>

<TABLE-GROUP ACLASS="SB_DT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">청약개시일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">청약종료일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">납입기일</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="SB_CO">주주배정</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUNIT="SB_STR_DT" AUNITVALUE="20221201">2022년 12월 01일</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUNIT="SB_END_DT" AUNITVALUE="20221202">2022년 12월 02일</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUNIT="PYM_DT" AUNITVALUE="20221209">2022년 12월 09일</TU>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">2. 인수기관별 인수금액</TITLE>

<TABLE-GROUP ACLASS="ACC_AMT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="139"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="97"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="148" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">인수기관</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">인수수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="116" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">인수금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비 율(%)</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="106" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비  고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="148" HEIGHT="30" ACODE="ACC_ORG">한국투자증권(주)</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACODE="ACC_CNT">11,026</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="116" HEIGHT="30" ACODE="ACC_AMT">277,855,200</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACODE="ACC_RT">0.12</TE>
<TE VALIGN="MIDDLE" WIDTH="106" HEIGHT="30" ACODE="NOTE" ALIGN="CENTER">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="148" HEIGHT="30" ACODE="ACC_ORG">케이비증권(주)</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACODE="ACC_CNT">11,026</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="116" HEIGHT="30" ACODE="ACC_AMT">277,855,200</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACODE="ACC_RT">0.12</TE>
<TE VALIGN="MIDDLE" WIDTH="106" HEIGHT="30" ACODE="NOTE" ALIGN="CENTER">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="148" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACODE="TOT_ACC_CNT">22,052</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="116" HEIGHT="30" ACODE="TOT_ACC_AMT">555,710,400</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACODE="TOT_ACC_RT">0.23</TE>
<TE VALIGN="MIDDLE" WIDTH="106" HEIGHT="30" ACODE="TOT_NOTE" ALIGN="CENTER">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>주1) '증권 인수업무 등에 관한 규정' 제9조 2항 5호에 따라 구주주 초과청약 배정 후 발생한 단수주를 공동대표주관회사인 한국투자증권(주)와 케이비증권(주)가 인수하였습니다.주2) 비율은 총 발행주식수인 9,562,408주를 기준으로 합니다.</P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">3. 청약 및 배정현황</TITLE>

<TABLE-GROUP ACLASS="DST_CD" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="1438" BORDER="0">

<COLGROUP>
<COL WIDTH="420"></COL>
<COL WIDTH="1000"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="429" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" WIDTH="1009" HEIGHT="30" AUNIT="WONSTOCKPERCENT" AUNITVALUE="1">(단위 : 원, 주, %)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="1439" BORDER="1">

<COLGROUP>
<COL WIDTH="174"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="116"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구  분</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="252" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최초 배정</TH>
<TH COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="504" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">청약 현황</TH>
<TH COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="500" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최종 배정 현황</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비율</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">건수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비율</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="125" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">건수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="125" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="125" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="125" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="183" HEIGHT="30" ACODE="DST_CD">신주인수권증서청약</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_CNT">9,562,408</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_RT">100</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_CNT">60,983</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_ST_CNT">8,860,632</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_AMT">223,287,926,400</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_RT">87.40</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_CNT">60,983</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_ST_CNT">8,860,632</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_AMT">223,287,926,400</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_RT">92.66</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="183" HEIGHT="30" ACODE="DST_CD">초과청약주식수</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_RT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_CNT">45,129</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_ST_CNT">1,276,820</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_AMT">32,175,864,000</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_RT">12.60</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_CNT">37,126</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_ST_CNT">679,724</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_AMT">17,129,044,800</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_RT">7.11</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="183" HEIGHT="30" ACODE="DST_CD">초과청약 배정 후 단수주</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_RT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_ST_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_AMT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_RT">-</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_CNT">1</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_ST_CNT">22,052</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_AMT">555,710,400</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_RT">0.23</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="183" HEIGHT="30" ACODE="DST_CD">실권주 일반공모</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_RT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_ST_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_AMT">-</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_RT">-</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_ST_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_AMT">-</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_RT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" WIDTH="183" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="FST_DV_CNT_TOT">9,562,408</TE>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30" AUPDATECONT="N">100</TD>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_CNT_TOT">106,112</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_ST_CNT_TOT">10,137,452</TE>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="30" ACODE="SB_AMT_TOT">255,463,790,400</TE>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30" AUPDATECONT="N">100</TD>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_CNT_TOT">98,110</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_ST_CNT_TOT">9,562,408</TE>
<TE ALIGN="RIGHT" WIDTH="125" HEIGHT="30" ACODE="DV_AMT_TOT">240,972,681,600</TE>
<TD ALIGN="RIGHT" WIDTH="125" HEIGHT="30" AUPDATECONT="N">100</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">4. 일반투자자 배정방식별 배정현황</TITLE>

<TABLE-GROUP ACLASS="NOR_ASS" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">배정수량(주)</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중(%)</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">균등방식 유형</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">균등방식</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="EQV_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="EQV_RT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="EQV_TYP">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">비례방식</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="PRP_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="PRP_RT">-</TE>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">-</TD>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="CNT_TOT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="RT_TOT">-</TE>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">-</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">5. 기관투자자 의무보유확약기간별 배정현황</TITLE>

<TABLE-GROUP ACLASS="INS_ASS" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="804" BORDER="0">

<COLGROUP>
<COL WIDTH="393"></COL>
<COL WIDTH="393"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="402" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="402" HEIGHT="30" AUNIT="STOCKPERCENT" AUNITVALUE="1">(단위 : 주, %)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="804" BORDER="1">

<COLGROUP>
<COL WIDTH="79"></COL>
<COL WIDTH="43"></COL>
<COL WIDTH="43"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">확약기간</TH>
<TH COLSPAN="8" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="410" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">국내 기관투자자</TH>
<TH COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="204" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">외국 기관투자자</TH>
<TH ROWSPAN="2" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="106" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">합계</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="104" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">운용사(집합)</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">투자매매ㆍ중개업자</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">연기금,운용사(고유)은행,보험</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">기타</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">거래실적유</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">거래실적무</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="30" ACODE="ASS_PRD">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="IN_MNG_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="IN_MNG_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BRK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BRK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BNK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BNK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_ETC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_ETC_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRY_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRY_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRN_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRN_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TOT_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TOT_RT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="30" AUPDATECONT="N">미확약</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="NIN_MNG_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="NIN_MNG_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BRK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BRK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BNK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BNK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_ETC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_ETC_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRY_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRY_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRN_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRN_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NTOT_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NTOT_RT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="TIN_MNG_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="TIN_MNG_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BRK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BRK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BNK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BNK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_ETC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_ETC_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRY_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRY_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRN_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRN_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TTOT_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TTOT_RT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-3-0">Ⅲ. 유상증자 전후의 주요주주 지분변동</TITLE>
<P></P>

<TABLE WIDTH="628" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="619"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="628" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위 : 주, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="631" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="171"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="54"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">성명</TH>
<TH ROWSPAN="2" WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">관 계</TH>
<TH ROWSPAN="2" WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">주식의종류</TH>
<TH COLSPAN="2" WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">증자 전</TH>
<TH COLSPAN="2" WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">증자 후</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">주식수</TH>
<TH WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">지분율</TH>
<TH WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">주식수</TH>
<TH WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">지분율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">진양곤</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">최대주주</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,610,902</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8.06</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,672,902</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7.45</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">이현아</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">친인척</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">230,772</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.22</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">230,772</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.20</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">이현수</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">임원</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">89,756</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.08</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">89,756</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.08</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">김용웅</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">임원</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,864</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.00</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,346</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.00</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">도순기</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">임원</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,864</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.00</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,346</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.00</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">에이치엘비생명과학(주)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">계열회사</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,399,230</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1.31</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,538,312</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1.32</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">에이치엘비셀(주)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">계열회사</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">828,214</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.77</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">910,537</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.78</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">진유림</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">친인척</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,230</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.01</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,230</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.01</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">진인혜</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">친인척</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,180</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.01</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,180</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.01</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="258" VALIGN="MIDDLE" ALIGN="CENTER" ROWSPAN="2" HEIGHT="60">소 계</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,185,012</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10.46</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,469,381</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9.85</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">우선주</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P>주1) 증자 전 발행주식총수 : 106,903,481주주2) 증자 후 발행주식총수 : 116,465,889주</P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-4-0">Ⅳ. 증권교부일 등</TITLE>
<P>- 증자 등기 예정일: 2022년 12월 12일 (등기 완료 예정일: 2022년 12월 14일)- 신주유통예정일 : 2022년 12월 23일- 상장 예정일: 2022년 12월 23일</P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-5-0">Ⅴ. 공시 이행상황</TITLE>
<P>1. 공고의 일자 및 방법</P>

<TABLE BORDER="1" WIDTH="642" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="222"></COL>
<COL WIDTH="144"></COL>
<COL WIDTH="249"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">구 분</TH>
<TH WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">공고일자</TH>
<TH WIDTH="258" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">공고방법</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">신주 발행 및배정기준일(주주확정일) 공고</TD>
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2022년 08월 12일</TD>
<TD WIDTH="258" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">당사 인터넷 홈페이지(http://www.hlbkorea.com)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">모집가액 확정의 공고</TD>
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">2022년 11월 29일</TD>
<TD WIDTH="258" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">전자공시시스템(http://dart.fss.or.kr)당사 인터넷 홈페이지(http://www.hlbkorea.com)</TD>
</TR>
</TBODY>
</TABLE>
<P>2. 증권신고서 : 전자문서 : 금융위(금감원) 전자공시시스템 →  http://dart.fss.or.kr3. 투자설명서 : - 전자문서 : 금융위(금감원) 전자공시시스템 → http://dart.fss.or.kr- 서면문서 : 에이치엘비㈜ → 울산광역시 울주군 온산읍 당월로 216-53                  케이비증권㈜ → 서울특별시 영등포구 여의나루로 50                  한국투자증권㈜ → 서울특별시 영등포구 의사당대로 88                  유진투자증권㈜ → 서울특별시 영등포구 국제금융로 24</P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-6-0">Ⅵ. 조달된 자금의 사용내역</TITLE>
<P></P>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">1. 자금조달 내용</TITLE>

<TABLE-GROUP ACLASS="INC_SL" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="597" BORDER="0">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="280"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="308" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="289" HEIGHT="30" AUNIT="WONSTOCK" AUNITVALUE="1">(단위 : 원, 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="598" BORDER="1">

<COLGROUP>
<COL WIDTH="39"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="63"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">주식구분</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="129" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">신고서상발행예정총액</TH>
<TH COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="286" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">실제 조달금액</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="72" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">발행가액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="79" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">수 량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="129" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">발행총액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="60" AUPDATECONT="N">모집</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="INC_RPT_MN">240,972,681,600</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="INC_STK_AMT">25,200</TE>
<TE ALIGN="RIGHT" WIDTH="79" HEIGHT="30" ACODE="INC_STK_CNT">9,562,408</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="INC_STK_TOT">240,972,681,600</TE>
<TE WIDTH="72" HEIGHT="30" ACODE="INC_NOTE" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="INC_RPT_TOT">240,972,681,600</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="INC_AMT_TOT">-</TE>
<TE ALIGN="RIGHT" WIDTH="79" HEIGHT="30" ACODE="INC_CNT_TOT">9,562,408</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="INC_TOT">240,972,681,600</TE>
<TE WIDTH="72" HEIGHT="30" ACODE="INC_NOTE_TOT" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="60" AUPDATECONT="N">매출</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACODE="SL_STK_KND">-</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="SL_RPT_MN">-</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SL_STK_AMT">-</TE>
<TE ALIGN="RIGHT" WIDTH="79" HEIGHT="30" ACODE="SL_STK_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="SL_STK_TOT">-</TE>
<TE WIDTH="72" HEIGHT="30" ACODE="SL_NOTE" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="SL_RPT_TOT">-</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SL_AMT_TOT">-</TE>
<TE ALIGN="RIGHT" WIDTH="79" HEIGHT="30" ACODE="SL_CNT_TOT">-</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="SL_TOT">-</TE>
<TE WIDTH="72" HEIGHT="30" ACODE="SL_NOTE_TOT" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" AUPDATECONT="N">총  계</TD>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="INC_SL_RPT_SUM">240,972,681,600</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="INC_SL_AMT_SUM">25,200</TE>
<TE ALIGN="RIGHT" WIDTH="79" HEIGHT="30" ACODE="INC_SL_CNT_SUM">9,562,408</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="INC_SL_SUM">240,972,681,600</TE>
<TE WIDTH="72" HEIGHT="30" ACODE="TOT_NOTE" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">2. 자금의 사용목적</TITLE>

<TABLE-GROUP ACLASS="INC_PRPS" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="934" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="625"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="634" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="934" BORDER="1">

<COLGROUP>
<COL WIDTH="125"></COL>
<COL WIDTH="125"></COL>
<COL WIDTH="125"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="124"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="134" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">시설자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="134" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">영업양수자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="134" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">운영자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="133" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">채무상환자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="133" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">타법인증권취득자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="133" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">기타</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="133" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">계</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TE WIDTH="134" HEIGHT="30" ACODE="FND_USE1" VALIGN="MIDDLE" ALIGN="RIGHT">20,700,000,000</TE>
<TE WIDTH="134" HEIGHT="30" ACODE="FND_USE_SQ" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="134" HEIGHT="30" ACODE="FND_USE2" VALIGN="MIDDLE" ALIGN="RIGHT">8,055,769,960</TE>
<TE WIDTH="133" HEIGHT="30" ACODE="FND_USE5" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="133" HEIGHT="30" ACODE="FND_USE_AS" VALIGN="MIDDLE" ALIGN="RIGHT">212,216,911,640</TE>
<TE WIDTH="133" HEIGHT="30" ACODE="FND_USE4" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="133" HEIGHT="30" ACODE="FND_USE_SUM" VALIGN="MIDDLE" ALIGN="RIGHT">240,972,681,600</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P USERMARK=" B">가. 공모자금 세부 사용목적</P>
<P>당사가 금번 유상증자를 통하여 조달할 예정인 자금은 약 2,410억원 규모이며, 자금의 분류별 세부 사용내역은 아래와 같습니다.</P>

<TABLE WIDTH="1042" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="733"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="742" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(외화단위: USD / 원화단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="1044" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="144"></COL>
<COL WIDTH="203"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="333"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">구분</TH>
<TH WIDTH="212" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">지급처</TH>
<TH WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">금액(외화)</TH>
<TH WIDTH="90" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">금액(원화)</TH>
<TH WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">사용 시기</TH>
<TH WIDTH="342" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="106" ROWSPAN="2">타법인증권취득자금</TD>
<TD WIDTH="212" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53"> 127,989,834</TD>
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">169,817</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2022년~2025년</TD>
<TD WIDTH="342" VALIGN="MIDDLE" HEIGHT="53">자회사의 유상증자를 통한기존 pipeline 임상비용 및 상업화 관련 비용 지원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="212" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Immunomic Therapeutics, Inc.</TD>
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53"> 31,956,587</TD>
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">42,400</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2023년 ~2025년</TD>
<TD WIDTH="342" VALIGN="MIDDLE" HEIGHT="53">종속회사의 유상증자를 통한 기존 pipeline 임상비용 지원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="365" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="2">시설자금</TD>
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,700</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2023년 ~2024년</TD>
<TD WIDTH="342" VALIGN="MIDDLE" HEIGHT="30">헬스케어사업부 둔곡 제2공장 건립 건축비 등</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="365" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">운영자금</TD>
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,056</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2023년</TD>
<TD WIDTH="342" HEIGHT="30" VALIGN="MIDDLE">복합소재 사업부문 원재료 매입 대금 등</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="365" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">240,973</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="342" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="1042" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1033"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1042" HEIGHT="99">주1) 자금의 사용목적 중 외화로 필요한 금액에 대하여는 2022년 11월28일 서울외국환중개 매매기준율(1,326.80원/달러)을 사용하여 산출하였으며, 상세 액수는 향후 당사의 주가 및 환율의 변동에 따라 변경될 수 있습니다.주2) 상기 일정은 내부 임상개발전략, 규제기관의 정책변화, 시장 변동에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>(1) 타법인증권취득자금당사는 금번 유상증자로 조달하는 금액 약 2,410억원 중 약 2,122억원을 타법인증권취득자금으로 사용할 예정이며, 그 세부 내용은 아래와 같습니다.</P>
<P></P>

<TABLE WIDTH="1099" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="790"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="799" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(외화단위: USD / 원화단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="1101" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="194"></COL>
<COL WIDTH="140"></COL>
<COL WIDTH="140"></COL>
<COL WIDTH="184"></COL>
<COL WIDTH="398"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="203" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지급처</TH>
<TH WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금액(외화)</TH>
<TH WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금액(원화)</TH>
<TH WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사용시기</TH>
<TH WIDTH="407" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">세부목적</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="203" VALIGN="MIDDLE" HEIGHT="53">Elevar Therapeutics Inc.</TD>
<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53"> 127,989,834</TD>
<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">169,817</TD>
<TD WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2022년 4분기부터지속적 지원</TD>
<TD WIDTH="407" VALIGN="MIDDLE" HEIGHT="53">자회사의 유상증자를 통한기존 pipeline 임상비용 및 상업화 관련 비용 지원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="203" VALIGN="MIDDLE" HEIGHT="53">Immunomic Therapeutics Inc.</TD>
<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53"> 31,956,587</TD>
<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">42,400</TD>
<TD WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2023년 1분기부터지속적 지원</TD>
<TD WIDTH="407" VALIGN="MIDDLE" HEIGHT="53">종속회사의 유상증자를 통한기존 pipeline 임상비용 지원</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="1099" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1090"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1099" HEIGHT="53">주1) 자금의 사용목적 중 외화로 필요한 금액에 대하여는 2022년 11월28일 서울외국환중개 매매기준율(1,326.80원/달러)을 사용하여 산출하였으며, 상세 액수는 향후 당사의 주가 및 환율의 변동에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1031" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1022"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1031" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[Elevar Therapeutics, Inc. 向 출자 계획]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1033">

<COLGROUP>
<COL WIDTH="110"></COL>
<COL WIDTH="198"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="113"></COL>
<COL WIDTH="128"></COL>
<COL WIDTH="104"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="74"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="119" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">예정 시기</TH>
<TH ROWSPAN="2" WIDTH="207" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">출자예정 대상회사</TH>
<TH ROWSPAN="2" WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">출자방법</TH>
<TH COLSPAN="2" WIDTH="259" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">출자예정금액</TH>
<TH WIDTH="113" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2" ALIGN="CENTER" HEIGHT="60">취득예정주식수</TH>
<TH COLSPAN="2" WIDTH="229" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">출자 이후</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="122" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">외화(달러)</TH>
<TH WIDTH="137" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">원화</TH>
<TH WIDTH="146" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">보유주식수(예정)</TH>
<TH WIDTH="83" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">지분율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2022년 4분기</TD>
<TD WIDTH="207" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 취득</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   14,485,981 </TD>
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 19,220,000,000</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,733,204 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">70,312,647 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">100.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2023년 2분기</TD>
<TD WIDTH="207" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 취득</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   17,794,694 </TD>
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 23,610,000,000</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,357,489 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">73,670,136 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">100.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2023년 4분기</TD>
<TD WIDTH="207" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 취득</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   32,936,388 </TD>
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 43,700,000,000</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,214,412 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">79,884,548 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">100.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2024년 2분기</TD>
<TD WIDTH="207" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 취득</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   27,492,614 </TD>
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 36,477,200,000</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,187,285 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">85,071,833 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">100.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2024년 4분기</TD>
<TD WIDTH="207" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 취득</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   29,388,604 </TD>
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 38,992,800,000</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,545,019 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">90,616,852 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">100.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2025년 2분기</TD>
<TD WIDTH="207" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 취득</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    4,168,273 </TD>
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 5,530,464,985</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">786,466 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">91,403,318 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">100.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2025년 4분기</TD>
<TD WIDTH="207" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Elevar Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 취득</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    5,891,552 </TD>
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 7,816,911,640</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,111,613 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">92,514,931 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">100.00%</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="1035" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1026"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1035" HEIGHT="30">주1) 상기 일정은 당사에서 계획중인  일정으로 규제기관의 정책변화, 시장 환경 변화, 내부 임상 개발 전략변경에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1054" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1045"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1054" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[Immunomic Therapeutics, Inc. 向 출자 계획]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1056">

<COLGROUP>
<COL WIDTH="110"></COL>
<COL WIDTH="233"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="125"></COL>
<COL WIDTH="98"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="65"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="119" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">예정 시기</TH>
<TH ROWSPAN="2" WIDTH="242" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">출자예정 대상회사</TH>
<TH ROWSPAN="2" WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">출자방법</TH>
<TH COLSPAN="2" WIDTH="262" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">출자예정금액</TH>
<TH WIDTH="107" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2" ALIGN="CENTER" HEIGHT="60">취득예정주식수</TH>
<TH COLSPAN="2" WIDTH="220" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">출자 이후</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="128" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">외화(달러)</TH>
<TH WIDTH="134" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">원화</TH>
<TH WIDTH="146" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">보유주식수(예정)</TH>
<TH WIDTH="74" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">지분율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2023년 1분기</TD>
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Immunomic Therapeutics, Inc.</TD>
<TD WIDTH="106" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">보통주 취득</TD>
<TD WIDTH="128" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">   19,972,867 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">26,500,000,000</TD>
<TD WIDTH="107" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">3,994,573 </TD>
<TD WIDTH="146" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">15,280,219 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">57.76%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2024년 1분기</TD>
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">Immunomic Therapeutics, Inc.</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">보통주 취득</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT">   11,983,720 </TD>
<TD WIDTH="134" HEIGHT="30" ALIGN="RIGHT">15,900,000,000</TD>
<TD WIDTH="107" HEIGHT="30" ALIGN="RIGHT">2,396,744 </TD>
<TD WIDTH="146" HEIGHT="30" ALIGN="RIGHT">17,676,963 </TD>
<TD WIDTH="74" HEIGHT="30" ALIGN="RIGHT">66.01%</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="1071" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1062"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1071" HEIGHT="30">주1) 상기 일정은 당사에서 계획중인 일정으로 규제기관의 정책변화, 시장 환경 변화, 내부 임상 개발 전략변경에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>당사는 당사의 자회사인 Elevar Therapeutics Inc.를 통하여 의약품개발(항암제 등) 사업을 영위하고 있습니다. 증권신고서 제출일 전일 현재 Elevar Therapeutics Inc. 는 신약후보물질 'Rivoceranib' 성분에 대해 중국을 제외한 글로벌 시장에서의 독점 실시권을 보유하고 있는 바, 연구개발 및 임상실험을 진행하여 최종적으로 신약 판매허가를 득하게 될 경우 그 제품에 대한 판권을 보유하게 됩니다.증권신고서 제출일 전일 현재 Elevar Therapeutics Inc. 는 다양한 적응증에 대하여 Rivoceranib 성분 단독 신약 및 타 성분과의 병용요법을 연구ㆍ개발 중에 있으며, 임상 진행 등에 있어서 지속적으로 자금 소요가 발생합니다. 이에 당사는 금번 유상증자를 통해 조달한 자금 중 약 1,698억원을 Elevar Therapeutics Inc.의 유상증자 참여에 사용할 예정이며, 그 중 1,494억원은 임상개발지원비용에, 204억원은 상업화를위한 마케팅 비용에 사용할 예정입니다. 유상증자 참여를 통해 당사가 Elevar Therapeutics Inc.에 지원하는 자금의 예상 사용처는 아래와 같습니다.① Elevar 임상 비용</P>

<TABLE WIDTH="1096" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="787"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="796" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(외화단위: USD / 원화단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="1097" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="335"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="117"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">
<P>내역</P>
</TH>

<TH WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">
<P>필요금액(외화)</P>
</TH>
<TH WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">필요금액(원화)</TH>
<TH WIDTH="504" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="4">연도별 사용 예정금액(원화)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2022</TH>
<TH WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2023</TH>
<TH WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2024</TH>
<TH WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2025</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>선낭양성암 1차 치료제 글로벌 단독임상 3상 비용</P>
</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   17,636,418</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">23,400</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,020 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,360 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,020 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">간암 1차 치료제 글로벌 임상 4상(PMS) 비용[Camrelizumab - Rivoceranib 병용]</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">   19,458,028</TD>

<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" USERMARK=" 0XC6AC4B B">
<SPAN USERMARK=" 0X000000 !B">25,817</SPAN>
</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">- </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">6,000 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">12,000 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">7,817</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>대장암 3차 치료제 글로벌 임상 2상 비용[론서프(타이호제약) - Rivoceranib 병용]</P>
</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">   10,174,857</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">13,500</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">5,400 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">8,100 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">대장암 3차 치료제 글로벌 임상 3상 비용[론서프(타이호제약) - Rivoceranib 병용]</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">   33,916,189</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">45,000</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">15,000 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">30,000 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">난소암(PR) 2차 치료제 글로벌 임상 1상 비용(아필리아 -   Rivoceranib 병용)</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">    9,044,317</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">12,000</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">4,800 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">7,200 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">난소암(PR) 2차 치료제 글로벌 임상 3상 비용(아필리아 -   Rivoceranib 병용)</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">   22,384,685</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">29,700</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">9,900 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">19,800 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="344" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 112,614,495</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">149,417</TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">17,220 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">55,560 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">68,820 </TD>
<TD WIDTH="126" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,817</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="1100" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1091"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1100" HEIGHT="53">주1) 자금의 사용목적 중 외화로 필요한 금액에 대하여는 2022년 11월28일 서울외국환중개 매매기준율(1,326.80원/달러)을 사용하여 산출하였으며, 상세 액수는 향후 당사의 주가 및 환율의 변동에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P>② Elevar 상업화 비용</P>

<TABLE WIDTH="979" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="670"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="679" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(외화단위: USD / 원화단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="982">

<COLGROUP>
<COL WIDTH="119"></COL>
<COL WIDTH="227"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="113"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="128" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">항목</TH>
<TH WIDTH="236" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내역</TH>

<TH WIDTH="123" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>필요금액(외화)</P>
</TH>
<TH WIDTH="123" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">필요금액(원화)</TH>
<TH WIDTH="372" HEIGHT="30" COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">연도별 사용 예정금액(원화)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="131" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2022</TH>
<TH WIDTH="119" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2023</TH>
<TH WIDTH="122" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2024</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">NDA 준비</TD>
<TD WIDTH="236" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">NDA 위한 전문 컨설팅</TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">   3,014,772 </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">4,000</TD>
<TD WIDTH="131" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">              2,000</TD>
<TD WIDTH="119" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">              2,000</TD>
<TD WIDTH="122" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">                   -</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">생산</TD>
<TD WIDTH="236" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">리보세라닙 시판용 제품 생산</TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">   5,275,852 </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">7,000</TD>
<TD WIDTH="131" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">                    -</TD>
<TD WIDTH="119" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">              4,000</TD>
<TD WIDTH="122" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">             3,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">온라인 마케팅</TD>
<TD WIDTH="236" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">온라인 홍보 (병원, 제약사 등) </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">   2,562,557 </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3,400</TD>
<TD WIDTH="131" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">                    -</TD>
<TD WIDTH="119" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">              2,350</TD>
<TD WIDTH="122" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">             1,050</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">오프라인 마케팅</TD>
<TD WIDTH="236" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">오프라인 홍보 (학회, 제약사 등) </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">   3,316,250 </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">4,400</TD>
<TD WIDTH="131" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">                    -</TD>
<TD WIDTH="119" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">              2,800</TD>
<TD WIDTH="122" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">             1,600</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">조직 관리</TD>
<TD WIDTH="236" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">협력업체 관리 및 운용 </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">   1,205,909 </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,600</TD>
<TD WIDTH="131" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">                    -</TD>
<TD WIDTH="119" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">                600</TD>
<TD WIDTH="122" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">             1,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="364" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE">
<P>합계</P>
</TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">  15,375,339 </TD>
<TD WIDTH="123" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">20,400</TD>
<TD WIDTH="131" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">              2,000</TD>
<TD WIDTH="119" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">            11,750</TD>
<TD WIDTH="122" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">             6,650</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="987" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="978"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="987" HEIGHT="53">주1) 자금의 사용목적 중 외화로 필요한 금액에 대하여는 2022년 11월 28일 서울외국환중개 매매기준율(1,326.80원/달러)을 사용하여 산출하였으며, 상세 액수는 향후 당사의 주가 및 환율의 변동에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P>또한, 증권신고서 제출일 현재 Immunomic Therapeutics Inc. 는 다양한 적응증에 대하여 UNITE (Universal Intracellular Targeted Expression)라는 면역 플랫폼 기술을활용하여 면역세포치료제, 치료백신 등의 면역치료제를 연구ㆍ개발 중에 있으며, 임상 진행 등에 있어서 지속적으로 자금 소요가 발생합니다. 이에 당사는 금번 유상증자를 통해 조달한 자금 중 약424억원을 Immunomic Therapeutics Inc.의 유상증자 참여에 사용할 예정입니다.</P>
<P>③ Immunomic Therapeutics 임상개발</P>

<TABLE WIDTH="957" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="648"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="657" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(외화단위: USD / 원화단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="956" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="208"></COL>
<COL WIDTH="149"></COL>
<COL WIDTH="149"></COL>
<COL WIDTH="132"></COL>
<COL WIDTH="132"></COL>
<COL WIDTH="132"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="217" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">
<P>내역</P>
</TH>

<TH WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">
<P>필요금액(외화)</P>
</TH>
<TH WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">필요금액(원화)</TH>
<TH WIDTH="423" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="3">연도별 사용 예정금액(원화)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="141" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2022</TH>
<TH WIDTH="141" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2023</TH>
<TH WIDTH="141" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2024</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="217" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>교모세포종 1차 치료제 GBM(ITI-1000) </P>
</TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53"> 31,956,587</TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">42,400</TD>
<TD WIDTH="141" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">-</TD>
<TD WIDTH="141" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">26,500</TD>
<TD WIDTH="141" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">15,900</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="956" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="947"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="956" HEIGHT="99">주1) 자금의 사용목적 중 외화로 필요한 금액에 대하여는 2022년 11월28일 서울외국환중개 매매기준율(1,326.80원/달러)을 사용하여 산출하였으며, 상세 액수는 향후 당사의 주가 및 환율의 변동에 따라 변경될 수 있습니다.주2) 전체 임상개발 필요비용 중 금번 유상증자 자금 424억원을 사용할 예정이며, 잔여 비용은 현지자금을 활용할 계획입니다. 주3) 상기 일정은 내부 임상개발전략, 규제기관의 정책변화, 시장 변동에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>당사가 계획중인 파이프라인 일정, 각 임상계획별 임상시험비용 세부내역 및 임상시험 개요는 아래와 같습니다</P>

<TABLE ACLASS="NORMAL" WIDTH="1369" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1360"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="1369" HEIGHT="338">
<P></P>

<IMAGE>
<IMG WIDTH="1360" HEIGHT="264" ALIGN="CENTER" HSPACE="0">파이프라인 일정_20220923.jpg</IMG>
<IMG-CAPTION ATOC="N">파이프라인 일정_20220923</IMG-CAPTION>
</IMAGE>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="1365" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1356"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1365" HEIGHT="30">주1) 상기 일정은 회사에서 추정한 일정으로 규제기관의 정책변화, 시장 환경 변화, 내부 임상 개발 전략변경에 따라 변경될 수 있습니다.</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>1) 선양낭성암 1차 치료제</P>

<TABLE WIDTH="1498" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="1189"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="1198" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1500">

<COLGROUP>
<COL WIDTH="222"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="322"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="62"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="231" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">파이프라인</TH>
<TH ROWSPAN="2" WIDTH="171" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구분</TH>
<TH ROWSPAN="2" WIDTH="331" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구성</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2022년</TH>
<TH COLSPAN="4" WIDTH="310" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2023년</TH>
<TH COLSPAN="4" WIDTH="308" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2024년</TH>
<TH ROWSPAN="2" WIDTH="71" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">총금액</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">1Q</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">1Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="7" WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="210">선양낭성암(ACC) 1차 치료제 3상 임상</TD>
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">CRO Opration</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,404 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    281 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    281 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    281 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    562 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,680</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">임상 사이트 관리(환자 검사비 등)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,755 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    585 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    585 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    585 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    585 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    439 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    439 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    439 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    439 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,850</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">데이터분석</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">통계 분석 비용</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    351 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    117 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    117 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    117 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    117 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     35 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     35 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     35 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    246 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,170</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상약 생산/유통</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">제조/유통</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,404 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    468 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    351 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    351 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    351 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    351 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,680</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상, NDA 컨설팅 등</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">컨설팅</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,053 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    983 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    281 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     70 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     70 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     53 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     53 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    316 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    632 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,510</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">기타 판관비</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">내부 운영비(출장, KOL 섭외, 인력보강 등)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,053 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    421 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    421 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    421 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    140 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    105 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    105 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    421 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    421 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,510</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="502" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,020</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,042</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,340</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,129</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,849</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,264</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,264</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,843</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,650</TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">23,400</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1326" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1317"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1326" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">[선양낭성암 1차 치료제 글로벌 임상 3상 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1327">

<COLGROUP>
<COL WIDTH="167"></COL>
<COL WIDTH="1142"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="1151" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="30">임상시험 대상국가</TD>
<TD WIDTH="1151" VALIGN="MIDDLE" HEIGHT="30">미국, 유럽, 아시아</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="53">임상시험의 목적</TD>
<TD WIDTH="1151" VALIGN="MIDDLE" HEIGHT="53">임상시험의 주요 목표는 재발 또는 전이성 선양낭성암(Adnoid Cystic Carcinoma, ACC) 피험자를 대상으로 대조군과 비교하여 리보세라닙의 안전성과 유효성을 확인하기 위함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">임상시험 시행 방법</TD>
<TD WIDTH="1151" VALIGN="MIDDLE" HEIGHT="99">시험 대상자 수: 재발 또는 전이성 선양낭성암 환자 약 156명 + 10% 환자 무작위(randomized), 이중눈가림(double-blind), 위약 대조로 진행되며, 리보세라닙 700mg과 위약을 투여하여 무진행생존기간(PFS)를 평가함 임상연구기간 : 전체 약 3년 (환자의 등록 상황 또는 투여기간 등에 따라 변동 가능)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="76">기대효과</TD>
<TD WIDTH="1151" VALIGN="MIDDLE" HEIGHT="76">선양낭성암의 진행은 혈관 형성과 밀접한 관계가 있는 것으로 알려져 있으며, 이러한 신생혈관은 VEGF와 VEGFR2에 의해 진행됨 리보세라닙은 신생혈관을 억제하는 표적항암제로 신생혈관의 주요한 표적인 VEGFR2를 타겟으로 하기 때문에 선양낭성암의 치료에 효과적일 것으로 기대됨.선양낭성암은 희귀질환으로 현재 표준치료제가 없기 때문에 리보세라닙의 신약 승인되면 최초의 신약이 될 것으로 기대됨 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="76">임상비용 산정근거 </TD>
<TD WIDTH="1151" VALIGN="MIDDLE" HEIGHT="76">American Medical Association의 조사에 따르면, 항암제 임상3상에 소요 되는 비용은 최소 31백만USD~59백만USD로 알려져 있습니다.실제 당사 과거 임상(GC3, ACC)에 투입된 비용을 분석한 결과, 환자 1인당 약 115천USD(한화 약150백만원)가 소요 되었습니다. 이를 근거로 향후 진행될 임상 비용을 산정하였으나 거시경제상황변화(물가상승, 환율), 임상프로토콜 수정 등에 의해 변동 가능성 또한 존재합니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">임상 시험 기관</TD>
<TD WIDTH="1151" VALIGN="MIDDLE" HEIGHT="99">미국: UCLA(University of California, Los Angeles), UCSF(San Francisco, Califonia), Dana-Farber Cancer Institute 등유럽: 협의중아시아: 서울대병원, 삼성서울병원 등(임상시험기관들과 논의후 추가 및 변경 가능)</TD>
</TR>
</TBODY>
</TABLE>
<P>2) 간암 (HCC) 1차 치료제 4상(PMS) 임상 </P>

<TABLE WIDTH="1507" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="1198"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="1207" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1509">

<COLGROUP>
<COL WIDTH="181"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="293"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="62"></COL>
<COL WIDTH="62"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="95"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="190" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">파이프라인</TH>
<TH ROWSPAN="2" WIDTH="171" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH ROWSPAN="2" WIDTH="302" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구성</TH>
<TH COLSPAN="4" WIDTH="248" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2023년</TH>
<TH COLSPAN="4" WIDTH="266" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2024년</TH>
<TH COLSPAN="4" WIDTH="228" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2025년</TH>
<TH ROWSPAN="2" WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">총금액 </TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="7" WIDTH="190" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="210">간암 (HCC) 1차 치료제 4상 임상 </TD>
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">CRO Opration</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">720 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">360 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">120 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 600 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">313</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">625</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">625</TD>
<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,163 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">임상 사이트 관리(환자 검사비 등)</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">450 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">450 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">750 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">750 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">750 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 750 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">684</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">353</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">586</TD>
<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,454 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">데이터분석</TD>
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">통계 분석 비용</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">210 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">30 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">30 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">30 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">150 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 150 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   150 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">150 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">137</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">254</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,291 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상약 생산/유통</TD>
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">제조/유통</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">480 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">240 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">240 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">240 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   600 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">469</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">547</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">547</TD>
<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  5,163 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상, NDA 컨설팅 등</TD>
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">컨설팅</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">360 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">180 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">180 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">180 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">450 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">450 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   450 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   450 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">645</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">235</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">293</TD>
<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,873 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">기타 판관비</TD>
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">내부 운영비(출장, KOL 섭외, 인력보강</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">225 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">225 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 225 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">225 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">450 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">450 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">450 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">   450 </TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">704</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">235</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">235</TD>
<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">      3,873 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="473" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,275</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,845</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,485</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,395</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,000</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,000</TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,000</TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,000</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,951</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,580</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,286</TD>
<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 25,817 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1326" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1317"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1326" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">[간암 1차 치료제 글로벌 임상 4상(PMS) 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1327">

<COLGROUP>
<COL WIDTH="165"></COL>
<COL WIDTH="1144"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="1153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="30">임상시험 대상국가</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="30">미국, 유럽, 아시아</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="30">임상시험의 목적</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="30">임상시험의 주요 목표는 절재 불가능한 간세포암(hepatocellular carcinoma, HCC) 피험자를 대상으로 리보세라닙과 캄렐리주맙 투여시 안전성과 내약성을 확인하기 위함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="99">임상시험 시행 방법</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="99">시험 대상자 수: 절재 불가능한 간세포암 환자 약 1,000명 리보세라닙과 캄렐리주맙을 투여받은 환자을 관찰하며 안전성과 내약성을 평가함 임상연구기간 : 전체 약 3년 (환자의 모집 상황 또는 투여기간 등에 따라 변동 가능)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="168">기대효과</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="168">- 간암의 진행은 혈관 형성과 밀접한 관계가 있는 것으로 알려져 있으며, 이러한 신생혈관은 VEGF와 VEGFR2에 의해 진행됨. 또한 종양미세환경내에서 면역억제로 인해 간암의 진행을 촉진하고 있음.- 리보세라닙은 신생혈관을 억제하는 표적항암제로 신생혈관의 주요한 표적인 VEGFR2를 타겟으로 하기 때문에 간암의 치료에 효과적일 것으로 기대되고, 캄렐리주맙은 종양미세환경의 면역억제기전을 정상화시켜 면역활성화를 통해 간암 치료에 효과적일 것으로 기대되고 있기 때문에 두 제품의 병용은 간암 치료에더욱 효과적일 것으로 기대됨- 간암은 1차 치료제는 넥사바, 렌비마와 같은 저분자 신생혈관억제제 단독치료제와 아바스틴(항체치료제)과 티센트릭(항체치료제) 병용으로 허가되어 있으며, 캄렐리주맙과 리보세라닙이 신약 승인되면 최초의 면역항암제+저분자신생혈관억제 병용 신약이 될 것으로 기대됨 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="30">임상비용 산정근거 </TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="30">글로벌 조사 기관인 ERG (Eastern Research Group Inc.)에 따르면, 항암제 임상4상에 소요 되는 비용은 최소 38백만USD로 알려져 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="99">임상 시험 기관</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="99">미국: MD Anderson, UCSC(University of California, San Diego), 등유럽: 협의중아시아: 서울아산병원, 삼성서울병원, 등(임상시험기관들과 논의후 추가 및 변경 가능)</TD>
</TR>
</TBODY>
</TABLE>
<P>3) 대장암 (CRC) 3차 치료제 2상 임상 </P>

<TABLE WIDTH="1175" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="866"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="875" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1176">

<COLGROUP>
<COL WIDTH="203"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="322"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="65"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="212" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">파이프라인</TH>
<TH ROWSPAN="2" WIDTH="171" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구분</TH>
<TH ROWSPAN="2" WIDTH="331" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구성</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2022년</TH>
<TH COLSPAN="4" WIDTH="310" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2023년</TH>
<TH ROWSPAN="2" WIDTH="74" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">총금액 </TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">1Q</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="7" WIDTH="212" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="210">대장암 (CRC) 3차 치료제  2상 임상</TD>
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">CRO Opration</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,080 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    162 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    162 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    324 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    972 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,700</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">임상 사이트 관리(환자 검사비 등)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,350 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    506 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    506 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    506 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    506 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,375</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">데이터분석</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">통계 분석 비용</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    270 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     41 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     41 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     81 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    243 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">675</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상약 생산/유통</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">제조/유통</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,080 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    405 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    405 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    405 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    405 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,700</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상, NDA 컨설팅 등</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">컨설팅</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    810 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    851 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    243 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     61 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     61 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,025</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">기타 판관비</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">내부 운영비(출장, KOL 섭외, 인력보강 등)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    810 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    365 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    365 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    365 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    122 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,025</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="502" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,400</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,329</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,721</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,742</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,309</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,500</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1333" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1324"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1333" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">[대장암 3차 치료제 글로벌 임상 2상 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1336">

<COLGROUP>
<COL WIDTH="167"></COL>
<COL WIDTH="1151"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="1160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="30">임상시험 대상국가</TD>
<TD WIDTH="1160" VALIGN="MIDDLE" HEIGHT="30">미국, 유럽, 아시아</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="30">임상시험의 목적</TD>
<TD WIDTH="1160" VALIGN="MIDDLE" HEIGHT="30">임상시험의 주요 목표는 전이성 대장암(Colorectal cancer, CRC) 피험자를 대상으로 리보세라닙과 트리플루리딘/티피라실(론서프) 투여시 안전성과 유효성을확인하기 위함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">임상시험 시행 방법</TD>
<TD WIDTH="1160" VALIGN="MIDDLE" HEIGHT="99">시험 대상자 수: 전이성 대장암 환자 약 100명 리보세라닙과 트리플루리딘/티피라실(론서프)을 투여받은 환자을 관찰하며 안전성과 유효성을 평가함 임상연구기간 : 전체 약 2년 (환자의 모집 상황 또는 투여기간 등에 따라 변동 가능)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">기대효과</TD>
<TD WIDTH="1160" VALIGN="MIDDLE" HEIGHT="99">- 대장암의 진행은 혈관 형성과 밀접한 관계가 있는 것으로 알려져 있으며, 이러한 신생혈관은 VEGF와 VEGFR2에 의해 진행됨.- 리보세라닙은 신생혈관을 억제하는 표적항암제로 신생혈관의 주요한 표적인 VEGFR2를 타겟으로 하기 때문에 간암의 치료에 효과적일 것으로 기대되고, 트리플루리딘/티피라실(론서프)은 새로운 세포독성항암제로 대장암 3차 치료제 단독요법으로 허가받아 효과적임을 증명되었음. 이러한 두 제품이 병용요법은 대장암 치료에 더욱 효과적일 것으로 기대됨.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="76">임상비용 산정근거 </TD>
<TD WIDTH="1160" VALIGN="MIDDLE" HEIGHT="76">American Medical Association의 조사에 따르면, 항암제 임상3상에 소요 되는 비용은 최소 31백만USD~59백만USD로 알려져 있습니다.실제 당사 과거 임상(GC3, ACC)에 투입된 비용을 분석한 결과, 환자 1인당 약 115천USD(한화 약150백만원)가 소요 되었습니다. 이를 근거로 향후 진행될 임상 비용을 산정하였으나 거시경제상황변화(물가상승, 환율), 임상프로토콜 수정 등에 의해 변동 가능성 또한 존재합니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">임상 시험 기관</TD>
<TD WIDTH="1160" VALIGN="MIDDLE" HEIGHT="99">미국: Vanderbilt University School of Medicine, Washington University School of Medicine 등유럽: 협의중아시아: 협의중(임상시험기관들과 논의후 추가 및 변경 가능)</TD>
</TR>
</TBODY>
</TABLE>
<P>4) 대장암 (CRC) 3차 치료제 3상 임상  </P>

<TABLE WIDTH="1277" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="968"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="977" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1280">

<COLGROUP>
<COL WIDTH="203"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="322"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="77"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="212" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">파이프라인</TH>
<TH ROWSPAN="2" WIDTH="171" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구분</TH>
<TH ROWSPAN="2" WIDTH="331" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구성</TH>
<TH COLSPAN="2" WIDTH="160" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2023년</TH>
<TH COLSPAN="4" WIDTH="320" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2024년</TH>
<TH ROWSPAN="2" WIDTH="86" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">총금액 </TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">1Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="7" WIDTH="212" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="210">대장암 (CRC) 3차 치료제  3상 임상 </TD>
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">CRO Opration</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    900 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  2,100 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">임상 사이트 관리(환자 검사비 등)</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  2,625 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,875 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,875 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,875 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,875 </TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,250 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">데이터분석</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">통계 분석 비용</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    525 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    225 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    375 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    375 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    375 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    375 </TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 2,250 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상약 생산/유통</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">제조/유통</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,500 </TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 9,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상, NDA 컨설팅 등</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">컨설팅</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,800 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    450 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,750 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">기타 판관비</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">내부 운영비(출장, KOL 섭외, 인력보강 등)</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,125 </TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 6,750 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="502" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,975</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,025</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,500</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,500</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,500</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,500</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">45,000 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1331" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1322"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1331" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">[대장암 3차 치료제 글로벌 임상 3상 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1333">

<COLGROUP>
<COL WIDTH="167"></COL>
<COL WIDTH="1148"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="1157" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="30">임상시험 대상국가</TD>
<TD WIDTH="1157" VALIGN="MIDDLE" HEIGHT="30">미국, 유럽, 아시아</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="30">임상시험의 목적</TD>
<TD WIDTH="1157" VALIGN="MIDDLE" HEIGHT="30">임상시험의 주요 목표는 전이성 대장암(Colorectal cancer, CRC) 피험자를 대상으로 리보세라닙과 트리플루리딘/티피라실(론서프) 투여시 안전성과 유효성을확인하기 위함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">임상시험 시행 방법</TD>
<TD WIDTH="1157" VALIGN="MIDDLE" HEIGHT="99">시험 대상자 수: 전이성 대장암 환자 약 500명 리보세라닙과 트리플루리딘/티피라실(론서프)을 투여받은 환자을 관찰하며 안전성과 유효성을 평가함 임상연구기간 : 전체 약 3년 (환자의 모집 상황 또는 투여기간 등에 따라 변동 가능)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">기대효과</TD>
<TD WIDTH="1157" VALIGN="MIDDLE" HEIGHT="99">- 대장암의 진행은 혈관 형성과 밀접한 관계가 있는 것으로 알려져 있으며, 이러한 신생혈관은 VEGF와 VEGFR2에 의해 진행됨.- 리보세라닙은 신생혈관을 억제하는 표적항암제로 신생혈관의 주요한 표적인 VEGFR2를 타겟으로 하기 때문에 간암의 치료에 효과적일 것으로 기대되고, 트리플루리딘/티피라실(론서프)은 새로운 세포독성항암제로 대장암 3차 치료제 단독요법으로 허가받아 효과적임을 증명되었음. 이러한 두 제품의 병용요법은 대장암 치료에 더욱 효과적일것으로 기대됨.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="76">임상비용 산정근거 </TD>
<TD WIDTH="1157" VALIGN="MIDDLE" HEIGHT="76">American Medical Association의 조사에 따르면, 항암제 임상3상에 소요 되는 비용은 최소 31백만USD~59백만USD로 알려져 있습니다.실제 당사 과거 임상(GC3, ACC)에 투입된 비용을 분석한 결과, 환자 1인당 약 115천USD(한화 약150백만원)가 소요 되었습니다. 이를 근거로 향후 진행될 임상 비용을 산정하였으나 거시경제상황변화(물가상승, 환율), 임상프로토콜 수정 등에 의해 변동 가능성 또한 존재합니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" HEIGHT="99">임상 시험 기관</TD>
<TD WIDTH="1157" VALIGN="MIDDLE" HEIGHT="99">미국: Vanderbilt University School of Medicine, Washington University School of Medicine 등유럽: 협의중아시아: 협의중(임상시험기관들과 논의후 추가 및 변경 가능)</TD>
</TR>
</TBODY>
</TABLE>
<P>5) 난소암 OC (PR) 2차 치료제 1상 임상 </P>

<TABLE WIDTH="1109" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="800"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="809" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1112">

<COLGROUP>
<COL WIDTH="222"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="322"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="59"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="231" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">파이프라인</TH>
<TH ROWSPAN="2" WIDTH="171" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구분</TH>
<TH ROWSPAN="2" WIDTH="331" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구성</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2022년</TH>
<TH COLSPAN="3" WIDTH="233" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2023년</TH>
<TH ROWSPAN="2" WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">총금액 </TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">1Q</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2Q</TH>
<TH WIDTH="77" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="7" WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="210">난소암 OC (PR) 2차 치료제  1상 임상</TD>
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">CRO Opration</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    960 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    576 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    720 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    144 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,400</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">임상 사이트 관리(환자 검사비 등)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,200 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    720 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    900 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    180 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">데이터분석</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">통계 분석 비용</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    240 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     72 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">     72 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    216 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상약 생산/유통</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">제조/유통</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    960 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    576 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    432 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    432 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,400</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상, NDA 컨설팅 등</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">컨설팅</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    720 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    216 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    216 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    648 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,800</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">기타 판관비</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">내부 운영비(출장, KOL 섭외, 인력보강 등)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    720 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    324 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    324 </TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    432 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,800</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="502" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,800</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,484</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,664</TD>
<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,052</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,000</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1327" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1318"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1327" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">[난소암(PR) 2차 치료제 글로벌 임상 1상 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1327">

<COLGROUP>
<COL WIDTH="168"></COL>
<COL WIDTH="1141"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="177" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="1150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="177" VALIGN="MIDDLE" HEIGHT="30">임상시험 대상국가</TD>
<TD WIDTH="1150" VALIGN="MIDDLE" HEIGHT="30">미국</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="177" VALIGN="MIDDLE" HEIGHT="53">임상시험의 목적</TD>
<TD WIDTH="1150" VALIGN="MIDDLE" HEIGHT="53">임상시험의 주요 목표는 백금계항암제 저항성(Platinum-resistant)이 있는 난소암(Platinum-resistant epithelial Ovarian Cancer) 피험자를 대상으로 리보세라닙과 아필리아 투여시 안전성과 유효성을 확인하기 위함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="177" VALIGN="MIDDLE" HEIGHT="99">임상시험 시행 방법</TD>
<TD WIDTH="1150" VALIGN="MIDDLE" HEIGHT="99">시험 대상자 수: 백금계항암제 저항성이 있는 난소암 환자 약 66 ~ 81명 아필리아와 리보세라닙의 투여시, 리보세라닙의 용량을 증가시키며 내약성과 안전성을 평가하여 용량을 결정임상연구기간 : 전체 약 2년 (환자의 모집 상황 또는 투여기간 등에 따라 변동 가능)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="177" VALIGN="MIDDLE" HEIGHT="76">기대효과</TD>
<TD WIDTH="1150" VALIGN="MIDDLE" HEIGHT="76">- 난소암의 진행은 혈관 형성과 밀접한 관계가 있는 것으로 알려져 있으며, 이러한 신생혈관은 VEGF와 VEGFR2에 의해 진행됨.- 리보세라닙은 신생혈관을 억제하는 표적항암제로 신생혈관의 주요한 표적인 VEGFR2를 타겟으로 하기 때문에 난소암의 치료에 효과적일 것으로 기대되고, 아필리아는 파클리탁셀(paclitaxel) 성분의 세포독성항암제로 난소암에 대해서 효과적임을 증명되었음. 이러한 두 제품의 병용요법은 난소암 치료에 더욱 효과적일 것으로 기대됨.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="177" VALIGN="MIDDLE" HEIGHT="76">임상비용 산정근거 </TD>
<TD WIDTH="1150" VALIGN="MIDDLE" HEIGHT="76">American Medical Association의 조사에 따르면, 항암제 임상3상에 소요 되는 비용은 최소 31백만USD~59백만USD로 알려져 있습니다.실제 당사 과거 임상(GC3, ACC)에 투입된 비용을 분석한 결과, 환자 1인당 약 115천USD(한화 약150백만원)가 소요 되었습니다. 이를 근거로 향후 진행될 임상 비용을 산정하였으나 거시경제상황변화(물가상승, 환율), 임상프로토콜 수정 등에 의해 변동 가능성 또한 존재합니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="177" VALIGN="MIDDLE" HEIGHT="53">임상 시험 기관</TD>
<TD WIDTH="1150" VALIGN="MIDDLE" HEIGHT="53">미국: GOG(gynecologic oncology group)과 협력하여 선정 예정(임상시험기관들과 논의후 추가 및 변경 가능)</TD>
</TR>
</TBODY>
</TABLE>
<P>6) 난소암 OC (PR) 2차 치료제 3상 임상 </P>

<TABLE WIDTH="1290" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="981"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="990" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1287">

<COLGROUP>
<COL WIDTH="222"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="322"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="65"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">파이프라인</TH>
<TH ROWSPAN="2" WIDTH="171" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH ROWSPAN="2" WIDTH="331" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구성</TH>
<TH COLSPAN="2" WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2023년</TH>
<TH COLSPAN="4" WIDTH="320" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2024년</TH>
<TH ROWSPAN="2" WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">총금액 </TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="80" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="7" WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="210">난소암 OC (PR) 2차 치료제  3상 임상</TD>
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">CRO Opration</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,188 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    792 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,940 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">임상 사이트 관리(환자 검사비 등)</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,485 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,238 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,238 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,238 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,238 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,425 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">데이터분석</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">통계 분석 비용</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    297 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    198 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    248 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    248 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    248 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    248 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,485 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상약 생산/유통</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">제조/유통</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    990 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 5,940 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상, NDA 컨설팅 등</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">컨설팅</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">  1,040 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    446 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 4,455 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">기타 판관비</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">내부 운영비(출장, KOL 섭외, 인력보강 등)</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">    743 </TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,455 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="502" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,742</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,158</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,950</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,950</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,950</TD>
<TD WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,950</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 29,700 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1327" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1318"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1327" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">[난소암(PR) 2차 치료제 글로벌 임상 3상 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1327">

<COLGROUP>
<COL WIDTH="165"></COL>
<COL WIDTH="1144"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="1153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="30">임상시험 대상국가</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="30">미국</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="53">임상시험의 목적</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="53">임상시험의 주요 목표는 백금계항암제 저항성(Platinum-resistant)이 있는 난소암(Platinum-resistant epithelial Ovarian Cancer) 피험자를 대상으로 리보세라닙과 아필리아 투여시 안전성과 유효성을 확인하기 위함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="99">임상시험 시행 방법</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="99">시험 대상자 수: 백금계항암제 저항성이 있는 난소암 환자 약 330명 아필리아와 리보세라닙를 투여받은 환자를 관찰하며 안전성과 유효성을 평가함 임상연구기간 : 전체 약 3년 (환자의 모집 상황 또는 투여기간 등에 따라 변동 가능)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="76">기대효과</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="76">- 난소암의 진행은 혈관 형성과 밀접한 관계가 있는 것으로 알려져 있으며, 이러한 신생혈관은 VEGF와 VEGFR2에 의해 진행됨.- 리보세라닙은 신생혈관을 억제하는 표적항암제로 신생혈관의 주요한 표적인 VEGFR2를 타겟으로 하기 때문에 난소암의 치료에 효과적일 것으로 기대되고, 아필리아는 파클리탁셀(paclitaxel) 성분의 세포독성항암제로 난소암에 대해서 효과적임을 증명되었음. 이러한 두 제품의 병용요법은 난소암 치료에 더욱 효과적일 것으로 기대됨.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="76">임상비용 산정근거 </TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="76">American Medical Association의 조사에 따르면, 항암제 임상3상에 소요 되는 비용은 최소 31백만USD~59백만USD로 알려져 있습니다.실제 당사 과거 임상(GC3, ACC)에 투입된 비용을 분석한 결과, 환자 1인당 약 115천USD(한화 약150백만원)가 소요 되었습니다. 이를 근거로 향후 진행될 임상 비용을 산정하였으나 거시경제상황변화(물가상승, 환율), 임상프로토콜 수정 등에 의해 변동 가능성 또한 존재합니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="174" VALIGN="MIDDLE" HEIGHT="53">임상 시험 기관</TD>
<TD WIDTH="1153" VALIGN="MIDDLE" HEIGHT="53">미국: GOG(gynecologic oncology group)과 협력하여 선정 예정(임상시험기관들과 논의후 추가 및 변경 가능)</TD>
</TR>
</TBODY>
</TABLE>
<P>7) 교모세포종 1차 치료제 GBM(ITI-1000) 3상 임상</P>
<P></P>

<TABLE WIDTH="1316" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="1007"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TD WIDTH="1016" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1317">

<COLGROUP>
<COL WIDTH="176"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="322"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="62"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="74"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="185" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">파이프라인</TH>
<TH ROWSPAN="2" WIDTH="171" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구분</TH>
<TH ROWSPAN="2" WIDTH="331" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구성</TH>
<TH COLSPAN="4" WIDTH="275" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2023년</TH>
<TH COLSPAN="4" WIDTH="272" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2024년</TH>
<TH ROWSPAN="2" WIDTH="83" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">총금액 </TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">1Q</TH>
<TH WIDTH="71" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2Q</TH>
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">1Q</TH>
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2Q</TH>
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">3Q</TH>
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="7" WIDTH="185" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="210">교모세포종 1차 치료제 GBM(ITI-1000)</TD>
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">CRO Opration</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,650 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,650 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,590 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,590 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,480 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상비용</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">임상 사이트 관리(환자 검사비 등)</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,313 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,313 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,988 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,988 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 10,600 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">데이터분석</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">통계 분석 비용</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,325 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">398 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">398 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,120 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상약 생산/유통</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">제조/유통</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,385 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,385 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,590 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,590 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,193 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,193 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,193 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,193 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 12,720 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">임상, NDA 컨설팅 등</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">컨설팅</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">663 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">663 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">636 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">159 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 2,120 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="171" VALIGN="MIDDLE" HEIGHT="30">기타 판관비</TD>
<TD WIDTH="331" VALIGN="MIDDLE" HEIGHT="30">내부 운영비(출장, KOL 섭외, 인력보강 등)</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">994 </TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">994 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">994 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">994 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 596 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">596 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">596 </TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 596 </TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,360 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="502" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,016</TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,004</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,584</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,896</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,379</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,776</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,412</TD>
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,333</TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 42,400 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="1318" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1309"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1318" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">[교모세포종 1차 치료제 글로벌 임상 3상 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1319">

<COLGROUP>
<COL WIDTH="151"></COL>
<COL WIDTH="1150"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="1159" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="160" VALIGN="MIDDLE" HEIGHT="30">임상시험 대상국가</TD>
<TD WIDTH="1159" VALIGN="MIDDLE" HEIGHT="30">미국</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="160" VALIGN="MIDDLE" HEIGHT="30">임상시험의 목적</TD>
<TD WIDTH="1159" VALIGN="MIDDLE" HEIGHT="30">임상시험의 주요 목표는 교모세포종(Glioblastoma, GBM) 피험자를 대상으로 대조군과 비교하여 ITI-1000의 안전성과 유효성을 확인하기 위함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="160" VALIGN="MIDDLE" HEIGHT="99">임상시험 시행 방법</TD>
<TD WIDTH="1159" VALIGN="MIDDLE" HEIGHT="99">시험 대상자 수: 교모세포종 환자 약 270명 ~ 600명 무작위(randomized), 위약 대조로 진행되며, ITI-1000과 위약을 투여하여 전체생존기간(OS)를 평가함  임상연구기간 : 전체 약 4.5년 (환자의 등록 상황 또는 투여기간 등에 따라 변동 가능)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="160" VALIGN="MIDDLE" HEIGHT="145">기대효과</TD>
<TD WIDTH="1159" VALIGN="MIDDLE" HEIGHT="145">교모세포종은 많은 환자에서 거대세포바이러스(Cytomegalovirus, CMV)가 발견되고 있기 때문에 좋은 타겟이 될 수 있음.  ITI-1000은 CMV의 항원을 UNITE 플랫폼인 리소좀관련막단백질(LAMP)에 발현시켜 환자의 면역세포를 빠르고 효율적으로 활성화시키는 기전을 가지고 있기 때문에 교모세포종 치료에 효과적일 것으로 기대됨. 교모세포종은 현재 세포독성항암제인 테모달 외에는 치료제가 없기 때문에 ITI-1000이 신약 승인되면 최초의 바이오신약이 될 것으로 기대됨 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="160" VALIGN="MIDDLE" HEIGHT="76">임상비용 산정근거 </TD>
<TD WIDTH="1159" VALIGN="MIDDLE" HEIGHT="76">American Medical Association의 조사에 따르면, 항암제 임상3상에 소요 되는 비용은 최소 31백만USD~59백만USD로 알려져 있습니다.환자 맞춤형 치료제의 특성상 환자별로 제조를 실시하여야 하기 때문에 일반적인 항암제에 비해 제조비용이 증가됩니다. 이를 근거로 향후 진행될 임상 비용을 산정하였으나 거시경제상황변화(물가상승, 환율), 임상프로토콜 수정 등에 의해 변동 가능성 또한 존재합니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="160" VALIGN="MIDDLE" HEIGHT="53">임상 시험 기관</TD>
<TD WIDTH="1159" VALIGN="MIDDLE" HEIGHT="53">미국: University of Florida, Duke University Medical Center 등(임상시험기관들과 논의후 추가 및 변경 가능)</TD>
</TR>
</TBODY>
</TABLE>
<P>상기 임상/NDA 진행 계획 및 자금 소요 예상 시기 등은 확정된 바가 아닌 당사의 목표이며, 당사의 의도와 관계 없이 예상치 못한 변수에 의해 변경되거나 취소될 가능성이 상존합니다. 상기 예정 사항이 불가피하게 변경 또는 취소되는 상황이 발생하는경우, 당사는 즉시 해당 내용에 대하여 공시를 통해 소명할 예정입니다.당사는 현재까지 미화 약 4억 2,577만 달러를 Elevar에, 미화 약  5,643만 달러를 Immunomic에 출자했습니다. 당사는 종속기업 지분 취득과 관련한 영업권 손상검토를 위해 매년 3분기말 외부회계법인을 통해 영업권 손상검토를 진행하고 있습니다.  이에따라 출자시 주식가치산정은 납입 이전 가장 최근 영업권손상검토보고서에 기재된수치를 사용하고 있습니다. </P>
<P>다만, 당사의 지속적인 출자에도 불구하고 Elevar와 Immunomic는 바이오연구개발기업의 특성상 유의미한 매출이 발생하고 있지 않으며, 연구개발비  및 판관비로 인한 자금지출이 지속적으로 이루어지고 있습니다. 특히, Elevar는 2021년 말 재무제표를 기준으로 전액자본잠식 상태이며 업종의 특수성을 고려하였을 때, 유의미한 연구개발결과가 나와 신약개발 매출로 이어지지 않는다면추가적인 재무구조 악화 및 자본잠식이 지속될 가능성이 높다고 판단됩니다.  당사가 금번 유상증자를 통해 조달하는 자금 중 Elevar 증권취득 목적으로 약 1,698억원(미화 약 1억 2,799만달러), Immunomic 증권취득 목적으로 약424억원(미화 약 3,196만달러)를 출자할 계획이며, 해당 출자에 따라 종속회사의 재무현황 개선이 기대됩니다. 다만, 해당 출자는 종속회사의 임상시험 일정에 따라 증자 납입 직후부터 2025년까지 상대적으로 길게 분포되어 있으며, 해당 출자에도 불구하고 연구개발비 증가 및 수익 발생 지연이 지속되는 경우 추가적인 재무구조 악화의 우려가 있습니다.  투자자분들께서는 당사의 종속기업인Elevar와 Immunomic의 이익 미실현 및 악화된 재무구조에 대해 인식하시고, 양 사의 연구개발 활동 지속을 위해서는 당사의 지속적인 출자가 필요하다는 점에 유의하시기 바랍니다. Elevar 및 Immunomic의 요약재무상태표는 아래와 같습니다.</P>

<TABLE WIDTH="776" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="446"></COL>
<COL WIDTH="312"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="776" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[Elevar 요약재무상태표]</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="455" VALIGN="MIDDLE" HEIGHT="30" USERMARK=" 0X54AF00 B">
<SPAN USERMARK=" 0X000000 !B">(US GAAP)</SPAN>
</TD>
<TD WIDTH="321" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> (단위: 천USD, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="776" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="254"></COL>
<COL WIDTH="255"></COL>
<COL WIDTH="240"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="263" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">결산연월 또는 결산기간</TH>
<TH WIDTH="264" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2021년</TH>
<TH WIDTH="249" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2020년</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">1. 자산총계</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">42,559</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">41,216</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">- 유동자산</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,767</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,383</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">2. 부채총계</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">55,254</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">39,265</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">- 유동부채</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">36,860</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,968</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">3. 자본총계</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(12,695)</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,951</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">4. 부채비율 (%)</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-435.2%</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2,012.6%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">5. 유동비율 (%)</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">59.1%</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">97.2%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">6. 영업손익</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(56,011)</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(31,317)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">기타 손익</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">825</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">536</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">7. 당기순이익</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(55,186)</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(30,781)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">8. 자본금</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">272,039</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">235,498</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">9. 영업활동 현금흐름</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(32,926)</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(35,882)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">10. 투자활동 현금흐름</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">652</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(20,202)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">11. 재무활동 현금흐름</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,267</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(6,084)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">12. 현금 및 현금성자산 기말 잔고</TD>
<TD WIDTH="264" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">19,644</TD>
<TD WIDTH="249" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,377</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="775" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="50"></COL>
<COL WIDTH="707"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="59" HEIGHT="30">자료 :</TD>
<TD WIDTH="716" HEIGHT="30">Elevar Therapeutics, Inc 감사보고서(KPMG LA)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="775" HEIGHT="53" COLSPAN="2">주1) Elevar는 외부감사 의무대상이 아니며, 회사 자체적으로 회계법인에 의뢰해 2020년 및 2021년 외부감사를 받았습니다. </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="741" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="446"></COL>
<COL WIDTH="277"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="741" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[Immunomic 요약재무상태표]</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="455" VALIGN="MIDDLE" HEIGHT="30">(K-IFRS) </TD>
<TD WIDTH="286" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> (단위: 천USD, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="744" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="254"></COL>
<COL WIDTH="152"></COL>
<COL WIDTH="151"></COL>
<COL WIDTH="151"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="263" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">결산연월 또는 결산기간</TH>
<TH WIDTH="161" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2021년</TH>
<TH WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2020년</TH>
<TH WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2019년</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">1. 자산총계</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">47,519 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">67,220 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,005 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">- 유동자산</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">31,331 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">47,546 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,825 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">2. 부채총계</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,080 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,933 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,515 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">- 유동부채</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,065 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,773 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,556 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">3. 자본총계</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">34,439 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">55,287 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,490 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">4. 부채비율 (%)</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">38.0%</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">21.6%</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">282.6%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">5. 유동비율 (%)</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">618.5%</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">1,260.2%</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">360.6%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">6. 영업손익</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,028 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">27 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,006 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">기타 손익</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(300)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(78)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">223 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">금융 손익</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(499)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(395)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(620)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">7. 당기순이익</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(23,210)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(10,699)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(5,107)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">8. 자본금</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">9. 영업활동 현금흐름</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(18,644)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(15,754)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(6,308)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">10. 투자활동 현금흐름</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(4,459)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,854)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(413)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">11. 재무활동 현금흐름</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(10)</TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">53,002 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(363)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" VALIGN="MIDDLE" HEIGHT="30">12. 현금 및 현금성자산 기말 잔고</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">23,484 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,597 </TD>
<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,204 </TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="744" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="49"></COL>
<COL WIDTH="677"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="58" HEIGHT="30">자료 :</TD>
<TD WIDTH="686" HEIGHT="30">Immunomic Therapeutics, Inc 감사보고서(삼일회계법인)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="744" HEIGHT="53" COLSPAN="2">주1) Immunomic은 외부감사 의무대상이 아니며, 회사 자체적으로 회계법인에 의뢰해 2021년 기준 최근 3개년 외부감사를 받았습니다. </TD>
</TR>
</TBODY>
</TABLE>
<P>당사가 금번 유상증자를 통해 조달하는 타법인(Elevar, Immunomic) 증권취득 목적 자금 약 2,122억원(미화 약 1억 5,994만 달러)의 사용 예정 시기는 증자 납입 직후부터 2025년까지 상대적으로 길게 분포되어 있습니다. (Elevar에 대한 당사의 세부 출자 계획은 본 증권신고서 "제1부 - III. 투자위험요소 - 2. 회사위험 - 나."를 참고하시기 바랍니다.) 이는 상기에 기재하였듯이 당사와 Elevar, Immunomic이 영위하는 사업의 특성상 자금 소요 시기를 확정적으로 예상하는 데 무리가 있기 때문입니다. 임상, NDA 및 상업화의 경우 연구 및 협상의 진행상황에 따라 당사가 본 증권신고서에기재한 일정보다 이르거나 늦게 진행될 가능성이 상존합니다.</P>
<P>(2) 시설자금 - 헬스케어 사업부 둔곡 제2공장 설립 ㈜에프에이는 2008년 5월에 설립되어 알코올 스왑 등 손소독제, 소독티슈 등을 생산하던 회사였으나 코로나의 등장과 확산으로 인하여 진단키트 수요가 폭발적으로 증가함에 따라 매출이 증가한 회사입니다. 당사는 인수 및 합병 이후 동사(現 헬스케어사업부)를 체외진단분야의 전문 기업으로 육성하여 해외의 신규시장으로의 진입을 시도할 것이며, 코로나 외 다른 분야로 사업을 확장시킬 목적을 가지고 있습니다. 당사는 기존 ㈜에프에이가 2020년 10월 매매계약을 체결했던 유성구 구룡동 대덕R&D특구에 위치한 연구시설용지에 둔곡 제2공장을 설립하여 기존 생산설비 이전, 기업부설 연구소 이전 및 확장으로 품질관리와 함께 연구,개발(R&D)의 체계를 구축할 계획입니다. </P>

<TABLE WIDTH="599" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="590"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="599" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[둔곡 제2공장 부지]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="600" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="600" HEIGHT="386">
<P></P>

<IMAGE>
<IMG WIDTH="591" HEIGHT="312" ALIGN="CENTER" HSPACE="0">둔곡 제2공장 부지.jpg</IMG>
<IMG-CAPTION ATOC="N">둔곡 제2공장 부지</IMG-CAPTION>
</IMAGE>
</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE WIDTH="816" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="807"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="816" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[자금의 세부 사용 계획]</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="816" ALIGN="RIGHT" HEIGHT="30">(단위 : 백만원) </TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="815" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="99"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="360"></COL>
<COL WIDTH="149"></COL>
<COL WIDTH="54"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH COLSPAN="2" WIDTH="225" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="369" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">내용</TH>
<TH WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">세부내역</TH>
<TH WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="108" VALIGN="MIDDLE" HEIGHT="30">신규시설투자</TD>
<TD WIDTH="117" VALIGN="MIDDLE" HEIGHT="30">건설공사</TD>
<TD WIDTH="369" VALIGN="MIDDLE" HEIGHT="30">건축, 토목, 기계설비, 전기설비, 통신설비, 소방설비</TD>
<TD WIDTH="158" VALIGN="MIDDLE" HEIGHT="30">둔곡 제2공장 설립</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,700</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="4" WIDTH="752" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,700</TD>
</TR>
</TBODY>
</TABLE>
<P>헬스케어사업부(舊 ㈜에프에이)는 2020년 10월 13일 한국토지주택공사와 대전광역시 유성구 구룡동 대덕R&D특구에 위치한 연구시설용지 총 12,196㎡ 를 56.65억원에 분양계약을 체결하여, 2021년 10월 29일 중도금 및 잔금 납부를 완료하였습니다.이후 연구소 이전 및 제품 라인업 강화의 전략적 검토 등으로 신규공장 건립이 지연됐으나, 2공장(둔곡) 신축을 위해 '22. 7월부터 공장 신축을 위한 기초 정보 수집(설비 및 시설 정보) 및 설계, 컨설팅 등 단계별 진행중에 있으며, 2023년 1월 설계 계약을 시작으로 2023년 6월 착공을 진행하여 최종 2024년 6월 공장 준공 및 설비 가동 셋팅 완료를 목표로 하고 있습니다. </P>
<P>(3) 운영자금</P>

<TABLE WIDTH="545" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="536"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="545" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[운영자금 상세 사용 목적]</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="545" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="545" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="154"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="143"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">사업명</TH>
<TH COLSPAN="2" WIDTH="230" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">사용시기</TH>
<TH ROWSPAN="2" WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">합계</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="115" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">2023년</TH>
<TH WIDTH="115" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">2024년</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">판매비와관리비</TD>
<TD WIDTH="115" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,871</TD>
<TD WIDTH="115" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,185</TD>
<TD WIDTH="152" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,056</TD>
</TR>
</TBODY>
</TABLE>
<P>금번 유상증자를 통한 공모 자금 중 약 8,056백만원은 당사 ENG 사업부의 운영자금으로 활용할 예정입니다. 당사의 별도기준 판매비와 관리비는 2019년 8,010백만원, 2020년 19,462백만원, 2021년 23,623백만원 등으로 매출액의 48.5%~79.3%를 차지하며, 2023년 판매비와관리비에 금번 유상증자 대금 중 일부를 활용할 계획입니다. 또한, 사용일까지는 특정금전신탁, MMDA 등 금융기관의 단기금융상품으로 운용할 예정입니다.</P>

<TABLE WIDTH="682" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="334"></COL>
<COL WIDTH="330"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="682" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="2">[영업비용 세부 내역]</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="343" VALIGN="MIDDLE" HEIGHT="30">(별도기준)</TD>
<TD WIDTH="339" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="682">

<COLGROUP>
<COL WIDTH="175"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="115"></COL>
<COL WIDTH="115"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="184" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구분</TH>
<TH WIDTH="119" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2022년 3분기</TH>
<TH WIDTH="131" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2021년</TH>
<TH WIDTH="124" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2020년</TH>
<TH WIDTH="124" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">2019년</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">급  여</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">3,613</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        4,410 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        3,967 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        2,801 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">퇴직급여</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">283</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          534 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           325 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           137 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">복리후생비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">584</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          585 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           620 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           452 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">여비교통비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">213</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          167 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           173 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           368 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">접대비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">295</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          291 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           270 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           169 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">통신비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">23</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            30 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            34 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            32 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">전력비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">35</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            64 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           139 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           122 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">세금과공과금</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">241</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          203 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           180 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           151 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">감가상각비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">865</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        1,097 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           989 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           598 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">지급임차료</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">390</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          437 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           159 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            99 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">보험료</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">159</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          294 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           177 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            62 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">차량유지비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">86</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          103 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            74 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            32 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">경상연구개발비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">408</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          244 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           285 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           233 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">소모품비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">16</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            32 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            50 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            50 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">지급수수료</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">188</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          123 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           186 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            85 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">광고선전비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">3,084</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        6,639 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        3,969 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        1,831 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">건물관리비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">4</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          150 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           265 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           273 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">대손상각비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">(81)</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">              0 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            36 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">              9 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">무형자산상각비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">8,724</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          723 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">              0 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">              3 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">주식보상비</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">-</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        7,273 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        7,263 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            17 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">판매보증비(환입)</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">(18)</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            78 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(66)</TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            37 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">기타</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">866</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">          146 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           368 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">           448 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" VALIGN="MIDDLE" HEIGHT="30">합   계</TD>
<TD WIDTH="119" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">20,059</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">      23,623 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">       19,462 </TD>
<TD WIDTH="124" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        8,010 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>당사는 금번 유상증자를 통하여 조달하는 자금을 본 증권신고서에 기재한 사용목적대로 사용하기 위해 최선의 노력을 다하고 있으며, 매 분기별 공시하는 당사의 정기보고서에 공모자금의 실제 사용내역 및 변동상황에 관하여 성실하게 공시할 예정입니다. 또한 자금의 조달 이후 실제 사용 시기까지 동 자금은 신용등급이 우량한 국내 적격금융기관의 수시입출금 예금, 정기예금, MMF 및 MMDA 등 안정성과 환금성을확보할 수 있는 금융상품에 예치할 계획입니다.</P>
<P></P>
</SECTION-3>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-7-0">Ⅶ. 신주인수권증서 발행내역</TITLE>
<P></P>

<LIBRARY>
<TABLE-GROUP ACLASS="SUBR_PUB" ADELETETABLE="N">
<TITLE ATOC="N">신주인수권증서 발행내역</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="283"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="308" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="292" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="54"></COL>
<COL WIDTH="128"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="125"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청구일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">발행시기</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="123" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청구자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="143" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">발행회사와의 관계</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="134" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">주식수</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUNIT="DMND_DT" AUNITVALUE="-">-</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="30" ACODE="PUB_PRD">2022년 10월 25일</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="123" HEIGHT="30" ACODE="DMNDER">한국예탁결제원</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="143" HEIGHT="30" ACODE="RLT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="134" HEIGHT="30" ACODE="ST_CNT">9,499,322</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="466" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="134" HEIGHT="30" ACODE="ST_TOT">9,499,322</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<TABLE-GROUP ACLASS="SUBR_SUB" ADELETETABLE="N">
<TITLE ATOC="N">신주인수권증서에 의한 청약내역</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="599" BORDER="0">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="282"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="308" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="291" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="599" BORDER="1">

<COLGROUP>
<COL WIDTH="128"></COL>
<COL WIDTH="161"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="140"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청약일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="170" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청약자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="143" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">발행회사와의 관계</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="149" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">주식수</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="53" AUNIT="SUB_DT" AUNITVALUE="20221202">2022년 12월 02일</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="170" HEIGHT="53" ACODE="SBER">한국예탁결제원(신주인수권증서 청약)</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="143" HEIGHT="53" ACODE="RLT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="149" HEIGHT="53" ACODE="ST_CNT">8,860,632</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="450" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="149" HEIGHT="30" ACODE="ST_TOT">8,860,632</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>

<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-8-0">Ⅷ. 실권주 처리내역</TITLE>
<P></P>
<P>1. 신주인수권증서 청약 실권주 및 단수주</P>

<TABLE WIDTH="601" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="284"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="308" HEIGHT="30"></TD>
<TD WIDTH="293" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위 : 주)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="602" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="192"></COL>
<COL WIDTH="192"></COL>
<COL WIDTH="191"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="201" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">신주인수권증서 청약 실권주</TH>
<TH WIDTH="201" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">구주주 배정 단수주</TH>
<TH WIDTH="200" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">실권주 및 단수주 총계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="201" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">638,690</TD>
<TD WIDTH="201" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">63,086</TD>
<TD WIDTH="200" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">701,776</TD>
</TR>
</TBODY>
</TABLE>
<P>주) 구주주 배정 단수주: 구주주 최초배정주식수 9,562,408주에서 구주주들에게 실제로 배정되어 발행된 신주인수권증서의 합인 9,499,322주를 차감한 단수주2. 신주인수권증서 청약 실권주 및 단수주 처리내역 : 초과청약 배정</P>

<TABLE WIDTH="754" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="437"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="308" HEIGHT="30"></TD>
<TD WIDTH="446" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위 : 주)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="755" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="199"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="150"></COL>
<COL WIDTH="251"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="208" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">신주인수권증서 청약 실권주및 구주주 배정 단수주</TH>
<TH WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">초과청약 주식수</TH>
<TH WIDTH="159" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">초과청약배정비율</TH>
<TH WIDTH="260" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비 고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="208" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">701,776</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">1,276,820</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">0.5496279820</TD>
<TD WIDTH="260" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">초과청약 배정 단수주 22,052주공동대표주관회사 인수</TD>
</TR>
</TBODY>
</TABLE>
<P>주) 구주주 청약 후 단수주 및 실권주는 초과청약되었으며, 초과청약 배정 이후 22,052주의 단수주는 공동대표주관회사인 한국투자증권(주), 케이비증권(주)가 자기계산으로 인수하였습니다.</P>
</SECTION-2>
</LIBRARY>

</SECTION-1>
</BODY>
</DOCUMENT>